autologous cryopreserved tumor (from the original source used for inoculation) 
and IL-2 . These lymph node lymphocytes will be given with systemic IL-2 
exactly as intended for TIL. 
III. PATIENT ELIGIBILITY 
The eligibility of patients for whom cell lines will be established and 
who will be offered the treatment portions of this protocol are the same and 
are listed below: 
1. Patients, age 18 or older, must have histologically confirmed 
metastatic cancer for which standard curative or palliative measures do not 
exist or are no longer effective. These patients have expected survivals of 
six months or less. 
2. The estimated tumor burden of the patient must be at least 10 grams 
which is 50 times the weight of tumor cells used for the immunization. 
3. Women of child bearing potential must have a negative pregnancy 
test. 
4. Patients must have a negative HIV test. 
5 . Patients must have a performance status less than 2 a nd must 
be free of active systemic infections and other major 
medical illnesses of the cardiovascular and respiratory systems. They should 
have the following laboratory values: 
a. white blood cell count greater than 3000/mm 3 
b. platelet count greater than 150,000/mm 3 
c. bilirubin less than 1.7 mg/dl 
d. creatinine less than 1.7 mg/dl 
6. Patients requiring steroid therapy will be excluded. 
7. Patients who have received therapy with cytotoxic agents, steroids., 
other biologies, or radiotherapy in the 4 weeks prior to cell inoculation will 
be excluded. 
IV. TREATMENT PLAN 
1. Summary. Tissue culture lines will be established from resected 
tumors during the course of normal patient treatment. The gene for 
Recombinant DNA Research, Volume 15 
[67] 
